NextCell Pharma | NextCell Pharma and The Stem Cell Revolution

NextCell's Product Portfolio

NextCell develops novel stromal cell therapies, with a primary focus on type 1 diabetes. The lead candidate ProTrans, is based on NextCell patented selection algorithm. NextCell also runs Cellaviva, Scandinavia's largest private stem cell bank.

About NextCell

NextCell is a Swedish biopharmaceutical company operating in three business areas – Cellaviva, ProTrans and QVance – with the shared core being cell therapies and development of advanced therapy medicinal products (ATMPs).

Investors

NextCell is listed on the Nasdaq First North Growth Market. Here you will find information about the share, the latest reports and other financial data.

News

2026-09-28

NextCell to present at the INNODIA Symposium during EASD 2026

Regulatory

NextCell Pharma AB (publ) (“NextCell” or the “Company”) has been invited to present its clinical development programme in type 1 diabetes at the INNODIA Symposium on T1D Therapies, held in connection with the European Association for the Study of Diabetes (EASD) 2026 meeting in Milan on 28 September. The presentation will focus on NextCell’s clinical programme for NXTCL-T1D, including long-term data from adult patients showing preservation of endogenous insulin production for more than six years following a single infusion.

Read more Read more

2026-08-27

Interim Report second quarter 2026

Regulatory

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Interim report for the second quarter 2026. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year. Please note that, as of 2025, the Company’s financial year corresponds to the calendar year.

Read more Read more

2026-08-18

NextCell Selected for EU-Japan Biotech Business Mission and Strengthens Presence in Hong Kong

Regulatory

NextCell Pharma AB ("NextCell" or the "Company") has been selected as the only Swedish company to participate in the EU-Japan Biotech Business Mission 2026. In parallel, the Company is strengthening its local presence in Hong Kong by establishing an office and becoming a member of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP), effective 1 September. NextCell will also participate as a Founding Partner in the Nordic Future Health Pavilion at BIOHK 2026, held 9–12 September.

Read more Read more

2026-05-28

Interim Report first quarter 2026

Regulatory

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Interim report for the first quarter 2026. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year. Please note that, as of 2025, the Company’s financial year corresponds to the calendar year.

NextCell – Part of the Stem Cell Revolution

NextCell's Product Portfolio

About NextCell

Investors

News

NextCell to present at the INNODIA Symposium during EASD 2026

Interim Report second quarter 2026

NextCell Selected for EU-Japan Biotech Business Mission and Strengthens Presence in Hong Kong

Interim Report first quarter 2026

Subscribe to press releases